Arghavan Salami is a biotech entrepreneur and the Founder & CEO of NanoLipo Cancer Solutions Ltd, a UK-based company developing a microfluidic liposomal drug delivery platform targeting multiple cancer types.

With direct and ongoing clinical exposure to cancer patients, Arghavan has developed a deep understanding of how patients navigate high-stakes treatment decisions and how cognitive biases, loss aversion, and present bias shape those choices in ways that traditional medicine rarely addresses.

This intersection of oncology and behavioural science is central to both her company’s mission and her academic research, which focuses on evidence-based interventions to improve treatment adherence in cancer care.